Global Osimertinib Mesylate Tablets 麻豆原创 Growth 2024-2030

Publication ID:

LPI11242231

Publication Date:

November 19, 2024

Pages:

105

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Osimertinib mesylate tablets are a medication used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations.These tablets are designed to inhibit the activity of the mutated EGFR, thereby slowing down or stopping cancer cell growth,which are often prescribed for patients with advanced or metastatic NSCLC who have developed resistance to other EGFR-targeted therapies.
The global Osimertinib Mesylate Tablets market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淥simertinib Mesylate Tablets Industry Forecast鈥� looks at past sales and reviews total world Osimertinib Mesylate Tablets sales in 2023, providing a comprehensive analysis by region and market sector of projected Osimertinib Mesylate Tablets sales for 2024 through 2030. With Osimertinib Mesylate Tablets sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Osimertinib Mesylate Tablets industry.
This Insight Report provides a comprehensive analysis of the global Osimertinib Mesylate Tablets landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Osimertinib Mesylate Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Osimertinib Mesylate Tablets market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Osimertinib Mesylate Tablets and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Osimertinib Mesylate Tablets.
United States market for Osimertinib Mesylate Tablets is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Osimertinib Mesylate Tablets is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Osimertinib Mesylate Tablets is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Osimertinib Mesylate Tablets players cover AstraZeneca, Zydus, Drug International, Beacon, General Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Osimertinib Mesylate Tablets market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Original Drug
Generic Drug
Segmentation by Application:
Hospital and Clinic
Retail Pharmacies
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Zydus
Drug International
Beacon
General Pharmaceuticals
Pharmacil
Wanbang Biopharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Osimertinib Mesylate Tablets market?
What factors are driving Osimertinib Mesylate Tablets market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Osimertinib Mesylate Tablets market opportunities vary by end market size?
How does Osimertinib Mesylate Tablets break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Osimertinib Mesylate Tablets Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Osimertinib Mesylate Tablets by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Osimertinib Mesylate Tablets by Country/Region, 2019, 2023 & 2030
2.2 Osimertinib Mesylate Tablets Segment by Type
2.2.1 Original Drug
2.2.2 Generic Drug
2.3 Osimertinib Mesylate Tablets Sales by Type
2.3.1 Global Osimertinib Mesylate Tablets Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Osimertinib Mesylate Tablets Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Osimertinib Mesylate Tablets Sale Price by Type (2019-2024)
2.4 Osimertinib Mesylate Tablets Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 Osimertinib Mesylate Tablets Sales by Application
2.5.1 Global Osimertinib Mesylate Tablets Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Osimertinib Mesylate Tablets Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Osimertinib Mesylate Tablets Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Osimertinib Mesylate Tablets Breakdown Data by Company
3.1.1 Global Osimertinib Mesylate Tablets Annual Sales by Company (2019-2024)
3.1.2 Global Osimertinib Mesylate Tablets Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Osimertinib Mesylate Tablets Annual Revenue by Company (2019-2024)
3.2.1 Global Osimertinib Mesylate Tablets Revenue by Company (2019-2024)
3.2.2 Global Osimertinib Mesylate Tablets Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Osimertinib Mesylate Tablets Sale Price by Company
3.4 Key Manufacturers Osimertinib Mesylate Tablets Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Osimertinib Mesylate Tablets Product Location Distribution
3.4.2 Players Osimertinib Mesylate Tablets Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Osimertinib Mesylate Tablets by Geographic Region
4.1 World Historic Osimertinib Mesylate Tablets 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Osimertinib Mesylate Tablets Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Osimertinib Mesylate Tablets Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Osimertinib Mesylate Tablets 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Osimertinib Mesylate Tablets Annual Sales by Country/Region (2019-2024)
4.2.2 Global Osimertinib Mesylate Tablets Annual Revenue by Country/Region (2019-2024)
4.3 Americas Osimertinib Mesylate Tablets Sales Growth
4.4 APAC Osimertinib Mesylate Tablets Sales Growth
4.5 Europe Osimertinib Mesylate Tablets Sales Growth
4.6 Middle East & Africa Osimertinib Mesylate Tablets Sales Growth
5 Americas
5.1 Americas Osimertinib Mesylate Tablets Sales by Country
5.1.1 Americas Osimertinib Mesylate Tablets Sales by Country (2019-2024)
5.1.2 Americas Osimertinib Mesylate Tablets Revenue by Country (2019-2024)
5.2 Americas Osimertinib Mesylate Tablets Sales by Type (2019-2024)
5.3 Americas Osimertinib Mesylate Tablets Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Osimertinib Mesylate Tablets Sales by Region
6.1.1 APAC Osimertinib Mesylate Tablets Sales by Region (2019-2024)
6.1.2 APAC Osimertinib Mesylate Tablets Revenue by Region (2019-2024)
6.2 APAC Osimertinib Mesylate Tablets Sales by Type (2019-2024)
6.3 APAC Osimertinib Mesylate Tablets Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Osimertinib Mesylate Tablets by Country
7.1.1 Europe Osimertinib Mesylate Tablets Sales by Country (2019-2024)
7.1.2 Europe Osimertinib Mesylate Tablets Revenue by Country (2019-2024)
7.2 Europe Osimertinib Mesylate Tablets Sales by Type (2019-2024)
7.3 Europe Osimertinib Mesylate Tablets Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Osimertinib Mesylate Tablets by Country
8.1.1 Middle East & Africa Osimertinib Mesylate Tablets Sales by Country (2019-2024)
8.1.2 Middle East & Africa Osimertinib Mesylate Tablets Revenue by Country (2019-2024)
8.2 Middle East & Africa Osimertinib Mesylate Tablets Sales by Type (2019-2024)
8.3 Middle East & Africa Osimertinib Mesylate Tablets Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Osimertinib Mesylate Tablets
10.3 Manufacturing Process Analysis of Osimertinib Mesylate Tablets
10.4 Industry Chain Structure of Osimertinib Mesylate Tablets
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Osimertinib Mesylate Tablets Distributors
11.3 Osimertinib Mesylate Tablets Customer
12 World Forecast Review for Osimertinib Mesylate Tablets by Geographic Region
12.1 Global Osimertinib Mesylate Tablets 麻豆原创 Size Forecast by Region
12.1.1 Global Osimertinib Mesylate Tablets Forecast by Region (2025-2030)
12.1.2 Global Osimertinib Mesylate Tablets Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Osimertinib Mesylate Tablets Forecast by Type (2025-2030)
12.7 Global Osimertinib Mesylate Tablets Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Osimertinib Mesylate Tablets Product Portfolios and Specifications
13.1.3 AstraZeneca Osimertinib Mesylate Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Zydus
13.2.1 Zydus Company Information
13.2.2 Zydus Osimertinib Mesylate Tablets Product Portfolios and Specifications
13.2.3 Zydus Osimertinib Mesylate Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Zydus Main Business Overview
13.2.5 Zydus Latest Developments
13.3 Drug International
13.3.1 Drug International Company Information
13.3.2 Drug International Osimertinib Mesylate Tablets Product Portfolios and Specifications
13.3.3 Drug International Osimertinib Mesylate Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Drug International Main Business Overview
13.3.5 Drug International Latest Developments
13.4 Beacon
13.4.1 Beacon Company Information
13.4.2 Beacon Osimertinib Mesylate Tablets Product Portfolios and Specifications
13.4.3 Beacon Osimertinib Mesylate Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Beacon Main Business Overview
13.4.5 Beacon Latest Developments
13.5 General Pharmaceuticals
13.5.1 General Pharmaceuticals Company Information
13.5.2 General Pharmaceuticals Osimertinib Mesylate Tablets Product Portfolios and Specifications
13.5.3 General Pharmaceuticals Osimertinib Mesylate Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 General Pharmaceuticals Main Business Overview
13.5.5 General Pharmaceuticals Latest Developments
13.6 Pharmacil
13.6.1 Pharmacil Company Information
13.6.2 Pharmacil Osimertinib Mesylate Tablets Product Portfolios and Specifications
13.6.3 Pharmacil Osimertinib Mesylate Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Pharmacil Main Business Overview
13.6.5 Pharmacil Latest Developments
13.7 Wanbang Biopharmaceuticals
13.7.1 Wanbang Biopharmaceuticals Company Information
13.7.2 Wanbang Biopharmaceuticals Osimertinib Mesylate Tablets Product Portfolios and Specifications
13.7.3 Wanbang Biopharmaceuticals Osimertinib Mesylate Tablets Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Wanbang Biopharmaceuticals Main Business Overview
13.7.5 Wanbang Biopharmaceuticals Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.